Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan

NCT00791830 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2013-01-08

No results posted yet for this study

Summary

Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients with kidney diseases and reduced renal function, but not among haemodialysis patients.

Haemodialysis patients often lose residual renal function after initiating dialysis leading to worsened quality of life, increased morbidity and mortality.

In this study an ARB is investigated in a double blind, randomised, parallel group, placebo controlled manner to see, if this ARB can save residual renal function among haemodialysis patients. Potential cardiovascular benefits of the treatment are also addressed.

Conditions

  • Kidney Failure, Chronic

Interventions

DRUG

Irbesartan

Tablets, 300 mg \* 1 daily, 1 year

DRUG

Placebo matching irbesartan 150 mg

Tablets, 300 mg \* 1 daily, 1 year

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Bente Jespersen, MD, DrMedSc · Department of Nephrology, Aarhus University Hospital, Skejby, Denmark

  • Erik Sloth, MD, DrMedSc · Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Skejby, Denmark

  • Jens Kristian D Jensen, MD, PhD · Department of Nephrology, Aarhus University Hospital, Skejby, Denmark

  • Krista D Kjærgaard, MD, PhD · Department of Nephrology, Aarhus University Hospital, Skejby, Denmark

  • Christian D Peters, MD · Department of Nephrology, Aarhus University Hospital, Skejby, Denmark

  • Charlotte Strandhave, MD · Department of Nephrology, Aalborg University Hospital, Denmark

  • Ida N Tietze, MD, PhD · Department of Internal Medicine, Region Hospital Viborg, Denmark

  • Marija K Novosel, MD · Department of Internal Medicine, Region Hospital Fredericia, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00791830 on ClinicalTrials.gov